Objectives
Angelab 1

This instrument will be designed to cover high risk patients. This system will use a LabonaChip to extract fetal DNA from the mother´s plasma based on differences in methylated pattern between fetus and mother and captured by specific magnetophoresis, plus qPCR for monogenic diseases with a known mutation.  The diseases will be:

  • Cystic Fibrosis (recessive disease, point mutation).
  • Spinal Muscular Atrophy (dominant disease deletion gene).
  • X-linked disorders.

To know more about the envisioned use of this system, please, check the envisioned future scenario described in this cartoon created by the consortium.

 

  1. 1
  2. 2
  3. 3
  4. 4